Sirolimus-eluting balloon offers potential “paradigm shift” in restenosis treatment
Treatment provided a promising alternative to standard care in repeat percutaneous coronary interventions in the first-of-a-kind trial.
List view / Grid view
Treatment provided a promising alternative to standard care in repeat percutaneous coronary interventions in the first-of-a-kind trial.
The FDA has awarded 11 grants equating to about $25 million of funding to clinical trials for the development of rare disease treatments.
Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD).
Sirolimus, which is used to prevent rejection after kidney transplants has been used to treat idiopathic pulmonary neuroendocrine cell hyperplasia...
FDA-approved drug holds promise for first effective treatment to prevent trauma-induced heterotopic ossification formation...